A further limitation is the use of AD-associated mutations in APP to drive pathology as these mutations alter the subcellular localization and processing of APP (Sasaguri et al., 2017), which may modulate the effect of trisomy of Hsa21 on these processes. This evidence concerns the gene APP and Alzheimer disease.